Drugs / CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)
CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01995708 | Jan 2014 → Jun 2022 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01995708 ↗ |
| Modality | Cell therapy | “autologous Langerhans-type dendritic cells (LCs) electroporated with CT7, MAGE-A3, and Wilms tumor 1 (WT1) messenger RNA (mRNA)” PMID 35100339 ↗ Mar 2022 |
| Route | Other | “Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant.” NCT01995708 ↗ |